Dashboard
Manage Tickers

ITRMIterum Therapeutics plc

Nasdaq iterumtx.com


$ 1.12 $ -0.07 (-5.88 %)    

Tuesday, 27-Aug-2024 15:59:29 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 476.68 $ 2.22 (0.47 %)
DIA $ 412.95 $ 0.69 (0.17 %)
SPY $ 561.57 $ 0.78 (0.14 %)
TLT $ 97.97 $ -0.17 (-0.17 %)
GLD $ 233.38 $ 0.62 (0.27 %)
$ 1.17
$ 1.19
$ 1.11 x 900
-- x --
$ 1.12 - $ 1.19
$ 0.62 - $ 2.50
253,354
na
26.57M
$ 1.41
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-13-2024 03-31-2024 10-Q
3 03-28-2024 12-31-2023 10-K
4 11-14-2023 09-30-2023 10-Q
5 08-11-2023 06-30-2023 10-Q
6 05-12-2023 03-31-2023 10-Q
7 03-16-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-12-2022 06-30-2022 10-Q
10 05-13-2022 03-31-2022 10-Q
11 03-28-2022 12-31-2021 10-K
12 11-12-2021 09-30-2021 10-Q
13 08-13-2021 06-30-2021 10-Q
14 05-14-2021 03-31-2021 10-Q
15 03-12-2021 12-31-2020 10-K
16 11-16-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-14-2020 03-31-2020 10-Q
19 03-12-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-14-2019 06-30-2019 10-Q
22 05-14-2019 03-31-2019 10-Q
23 03-25-2019 12-31-2018 10-K
24 11-14-2018 09-30-2018 10-Q
25 08-14-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-maintains-buy-on-iterum-therapeutics-lowers-price-target-to-5
HC Wainwright & Co. Maintains Buy on Iteru...
08/15/2024 11:10:47

HC Wainwright & Co. analyst Ed Arce maintains Iterum Therapeutics (NASDAQ:ITRM) with a Buy and lowers the price target f...

iterum-therapeutics-q2-2024-adj-eps-023-beats-045-estimate-cash-cash-equivalents-and-short-term-investments-were-117m-will-be-sufficient-to-fund-its-operations-into-2025
Iterum Therapeutics Q2 2024 Adj. EPS $(0.2...
08/14/2024 11:07:05

iterum-therapeutics-announces-expiration-and-results-of-rights-offering-estimates-that-it-will-receive-aggregate-gross-proceeds-of-74m-not-including-estimated-expenses-relating-to-the-rights-offering-and-payable-by-the-company-of-11m
Iterum Therapeutics Announces Expiration A...
08/06/2024 21:35:28

Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company"), a clinical-stage pharmaceutical company focused on developing ne...

iterum-therapeutics-announces-uspto-notice-of-allowance-for-two-us-patents-and-issuance-of-canadian-patent-by-cipo-for-sulopenem-etzadroxil-and-probenecid-oral-sulopenem
Iterum Therapeutics Announces USPTO Notice...
08/02/2024 12:04:11

iterum-therapeutics-commences-121-per-unit-rights-offering-for-antibiotics-development
Iterum Therapeutics Commences $1.21 Per Un...
07/22/2024 11:43:09

Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company"), a clinical-stage pharmaceutical company focused on developing ne...

hc-wainwright--co-reiterates-buy-on-iterum-therapeutics-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Iter...
06/21/2024 17:40:20

HC Wainwright & Co. analyst Ed Arce reiterates Iterum Therapeutics (NASDAQ:ITRM) with a Buy and maintains $6 price target.

iterum-therapeutics-announces-fda-to-review-new-drug-application-for-oral-sulopenem-etzadroxilprobenecid-for-uncomplicated-utis-in-advisory-committee-meeting-on-september-9-2024-discussion-to-focus-on-antimicrobial-stewardship-and-target-patient-population
Iterum Therapeutics Announces FDA To Revie...
06/21/2024 12:02:20

hc-wainwright--co-reiterates-buy-on-iterum-therapeutics-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Iter...
05/31/2024 16:40:39

HC Wainwright & Co. analyst Ed Arce reiterates Iterum Therapeutics (NASDAQ:ITRM) with a Buy and maintains $6 price target.

iterum-therapeutics-announced-that-the-us-fda-has-acknowledged-receipt-of-the-resubmission-of-the-nda-for-sulopenem-etzadroxilprobenecid-for-the-treatment-of-utis
Iterum Therapeutics Announced That The U.S...
05/31/2024 12:03:15

hc-wainwright--co-reiterates-buy-on-iterum-therapeutics-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Iter...
05/14/2024 10:41:55

HC Wainwright & Co. analyst Ed Arce reiterates Iterum Therapeutics (NASDAQ:ITRM) with a Buy and maintains $6 price target.

iterum-therapeutics-cash-cash-equivalents-and-short-term-investments-were-182-million-at-march-31-2024-will-be-sufficient-to-fund-its-operations-into-2025
Iterum Therapeutics' Cash, Cash Equivalent...
05/13/2024 11:03:43

iterum-therapeutics-q1-2024-adj-eps-058-beats-072-estimate
Iterum Therapeutics Q1 2024 Adj EPS $(0.58...
05/13/2024 11:02:41

hc-wainwright--co-reiterates-buy-on-iterum-therapeutics-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Iter...
04/30/2024 10:37:41

HC Wainwright & Co. analyst Ed Arce reiterates Iterum Therapeutics (NASDAQ:ITRM) with a Buy and maintains $6 price target.

iterum-therapeutics-resubmits-new-drug-application-to-fda-for-oral-sulopenem
Iterum Therapeutics Resubmits New Drug App...
04/29/2024 12:03:18

on-april-3-iterum-therapeutics-received-letter-from-nasdaq-indicating-that-it-is-not-in-compliance-with-nasdaq-listing-rule
On April 3, Iterum Therapeutics Received L...
04/05/2024 20:36:30

- SEC Filing

hc-wainwright--co-reiterates-buy-on-iterum-therapeutics-maintains-6-price-target
HC Wainwright & Co. Reiterates Buy on Iter...
04/01/2024 10:23:51

HC Wainwright & Co. analyst Ed Arce reiterates Iterum Therapeutics (NASDAQ:ITRM) with a Buy and maintains $6 price target.

update-iterum-therapeutics-q4-adjusted-eps-081-beats-094-estimate
Update: Iterum Therapeutics Q4 Adjusted EP...
03/28/2024 12:56:37

Iterum Therapeutics (NASDAQ:ITRM) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $...

iterum-therapeutics-q4-adj-eps-081-beats-093-estimate
Iterum Therapeutics Q4 Adj EPS $(0.81) Bea...
03/28/2024 12:50:17

Iterum Therapeutics (NASDAQ:ITRM) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $...

earnings-scheduled-for-march-28-2024
Earnings Scheduled For March 28, 2024
03/28/2024 09:24:44

Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per ...

iterum-therapeuticss-earnings-a-preview
Iterum Therapeutics's Earnings: A Preview
03/27/2024 17:01:36

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION